Table 4.
Studies demonstrating a decrease in HbA1c after iron substitution therapy (HbA1c values are given as mean ± SD or [95% confidence interval])
| Reference | Population | n | HbA1c before treatment | HbA1c after treatment | Difference in mean HbA1c | Treatment |
|---|---|---|---|---|---|---|
| Davis 1983 [30] | 68-year-old woman with IDA and DM | 1 |
10.7% (without IDA) 15.4% (with IDA) |
11% | 4.4% | Not disclosed |
| Tarim 1999 [5] | Patients with type 1 DM and ID | 11 | 10.6% ± 2.6% | 8.3% ± 2.6% | 2.3% (P < 0.05) | Oral 6 mg/kg/day for 3 months |
| Tarim 1999 [5] | Nondiabetic patients with ID | 11 | 7.7% ± 1.3% | 6.4% ± 1.2% | 1.3% (P < 0.05) | Oral 6 mg/kg/day for 3 months |
| El-Agouza 2002 [7] | Students with IDA | 51 | 6.15% ± 0.62% | 5.25% ± 0.45% | 0.9% (P < 0.001) | Oral ferrous sulphate 325 mg/day for 20 weeks |
| Coban 2004 [6] | Nondiabetic patients with IDA | 50 | 7.4% ± 0.8% | 6.2% ± 0.6% | 1.2% (P < 0.001) | Oral 100 mg/day for 3 months |
| Ng 2010 [22] | Patients with type 2 DM and chronic kidney disease | 15 | 7.40% [6.60–8.19] | 6.96% [6.27–7.25] | 0.4% (P < 0.001) | Single dose of low molecular weight iron dextran as IV infusion |